HIGH DOSE SEQUENTIALCHEMOTHERAPY WITH RITUXIMAB AND ASCT AS FIRST LINE THERAPY IN ADULT MCL PATIENTS: CLINICAL AND MOLECULARRESPONSE OF THE MCL0208 TRIAL, A FIL STUDY

被引：0

作者：

Cortelazzo, S. ^{[1
]}

Martelli, M. ^{[2
]}

Ladetto, M. ^{[3
]}

Ferrero, S. ^{[4
]}

Ciccone, G. ^{[5
]}

Evangelista, A. ^{[5
]}

Mian, M. ^{[6
]}

Di Rocco, A. ^{[2
]}

Chiappella, A. ^{[7
]}

Rossi, G. ^{[8
]}

Re, A. ^{[9
]}

Zinzani, P. L. ^{[10
]}

Balzarotti, M. ^{[11
]}

Cavallo, F. ^{[4
]}

Rusconi, C. ^{[12
]}

Gotti, M. ^{[13
]}

Arcaini, L. ^{[13
]}

Gobbi, M. ^{[14
]}

Gomes, M. ^{[15
]}

Molinari, A. ^{[16
]}

Liberati, A. M. ^{[17
]}

Michieli, M. ^{[18
]}

Latte, G. ^{[19
,20
]}

Cabras, M. G. ^{[21
]}

Novero, D. ^{[22
]}

Paulli, M. ^{[23
]}

Zamo, A. ^{[24
,25
]}

Chilosi, M. ^{[24
,25
]}

Federico, M. ^{[26
]}

Vitolo, U. ^{[7
]}

机构：

[1] Ist Clin Humanitas Gavazzeni, Unita Oncol Med & Ematol, Hematol, Bergamo, Italy

[2] Univ Roma La Sapienza, Dip Biotecnol Cellulari & Ematol, Hematol, I-00185 Rome, Italy

[3] AO SS Antonio & Biagio, SC Ematol, Hermatol, Alessandria, Italy

[4] SCDU Ematol Univ, AO Citta Salute & Sci, Hematol, Turin, Italy

[5] AO Citta Salute & Sci, CPO Piemonte Ctr Riferimento Epidemiol & Prevenz, Epidemiol, Turin, Italy

[6] Med Univ Innsbruck, Dept Hematol & Oncol, Hematol, A-6020 Innsbruck, Austria

[7] AO Citta Salute & Sci, SC Ematol, Hematol, Turin, Italy

[8] Spedali Civil Brescia, SC Ematol, Hematol, I-25125 Brescia, Italy

[9] Spedali Civil Brescia, SC Ematol, Hermatol, I-25125 Brescia, Italy

[10] St Orsola Marcello Malpighi Hosp, Ist Ematol & Oncol Med Seragnoli, Hematol, Bologna, Italy

[11] Ist Clin Human, Hematol Oncol Med & Ematol, Rozzano, Italy

[12] Osped Maggiore Niguarda, Div Ematol, Hematol, Milan, Italy

[13] Fdn IRCCS Policlin San Matteo, Dipartimento Ematol Oncol, Hematol, Pavia, Italy

[14] IRCCS AOU San Martino IST, Clin Ematol, Hematol, Genoa, Italy

[15] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Hematol, Lisbon, Portugal

[16] Osped Infermi, UO Ematol, Hematol, Rimini, Italy

[17] Osped Santa Maria, Struttura Complessa Oncoematol, Hematol, Terni, Italy

[18] Med A Ctr Riferimento Oncol, Oncol, Aviano, Italy

[19] UOC Ematol, Hematol, Nuoro, Italy

[20] CTMO Presidio Osped S Francesco, Nuoro, Italy

[21] Osped Businco, Div Ematol, Hematol, Cagliari, Italy

[22] AO Citta Salute & Sci, Anat Patol, Pathol, Turin, Italy

[23] Dipartimento Sci Pediat & Patol Umana, Sez Anat Patol, Pathol, Pavia, Italy

[24] Univ Verona, Dipartimento Patol & Diagnost, Pathol, I-37100 Verona, Italy

[25] AOUI Verona, Verona, Italy

[26] Univ Modena & Reggio Emilia, Policlin, COM Ctr Oncol Modenese, Oncol,Dipartimento Oncol & Ematol, Modena, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S106

引用

页码：3 / 4

页数：2

共 50 条

[1] Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial
Clerico, Michele
Ferrero, Simone
Alessandria, Beatrice
Zaccaria, Gian Maria
Genuardi, Elisa
Ragaini, Simone
Tavarozzi, Rita
Cavallo, Federica
Hohaus, Stefan
Musuraca, Gerardo
Carella, Angelo Michele
Stelitano, Caterina
Tani, Monica
Gaidano, Gianluca
Olivieri, Jacopo
Usai, Sara Veronica
Galimberti, Sara
Re, Francesca
Mian, Michael
Castellino, Claudia
Pavone, Vincenzo
Evangelista, Andrea
Bruno, Benedetto
Cortelazzo, Sergio
Passera, Roberto
Ladetto, Marco
SCIENTIFIC REPORTS, 2024, 14 (01):
[2] A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
Zaccaria, Gian Maria
Ferrero, Simone
Hoster, Eva
Passera, Roberto
Evangelista, Andrea
Genuardi, Elisa
Drandi, Daniela
Ghislieri, Marco
Barbero, Daniela
Del Giudice, Ilaria
Tani, Monica
Moia, Riccardo
Volpetti, Stefano
Cabras, Maria Giuseppina
Di Renzo, Nicola
Merli, Francesco
Vallisa, Daniele
Spina, Michele
Pascarella, Anna
Latte, Giancarlo
Patti, Caterina
Fabbri, Alberto
Guarini, Attilio
Vitolo, Umberto
Hermine, Olivier
Kluin-Nelemans, Hanneke C.
Cortelazzo, Sergio
Dreyling, Martin
Ladetto, Marco
CANCERS, 2022, 14 (01)
[3] HIGH DOSE THERAPY AND STEM CELL RESCUE IN MANTLE CELL LYMPHOMA: THE MCL0208 TRIAL FROM FONDAZIONE ITALIANA LINFOMI
Clerico, M.
Ferrero, S.
Alessandria, B.
De Luca, G.
Grimaldi, D.
Genuardi, E.
Zaccaria, G. M.
Drandi, D.
Cavallo, F.
Mantoan, B.
Ghislieri, M.
Hohaus, S.
Musuraca, G.
Scalzulli, P. R.
Ghiggi, C.
Tani, M.
Gaidano, G.
Volpetti, S.
Cabras, G.
Di Renzo, N.
Merli, F.
Vallisa, D.
Michieli, M.
Pascarella, A.
Cortelazzo, S.
Ladetto, M.
HAEMATOLOGICA, 2021, 106 (10) : 18 - 18
[4] TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONEITALIANA LINFOMI (FIL)
Ferrero, S.
Rossi, D.
Bruscaggin, A.
Ghione, P.
Di Rocco, A.
Spina, V.
Stefoni, V.
Ciccone, G.
Barbero, D.
Monitillo, L.
Gomes da Silva, M.
Santoro, A.
Molinari, A.
Ferreri, A.
Piccin, A.
Cortelazzo, S.
Ladetto, M.
Gaidano, G.
HAEMATOLOGICA, 2016, 101 : S58 - S58
[5] TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONE ITALIANA LINFOMI (FIL)
Ferrero, S.
Rossi, D.
Bruscaggin, A.
Ghione, P.
Di Rocco, A.
Spina, V.
Stefoni, V.
Ciccone, G.
Barbero, D.
Monitillo, L.
Gomes da Silva, M.
Santoro, A.
Molinari, A.
Ferreri, A.
Piccin, A.
Cortelazzo, S.
Ladetto, M.
Gaidano, G.
HAEMATOLOGICA, 2016, 101 : 272 - 272
[6] Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
Zaccaria, Gian Maria
Ferrero, Simone
Evangelista, Andrea
Rosati, Samanta
Castagneri, Cristina
Ghislieri, Marco
Daniela, Barbero
Genuardi, Elisa
Lo Schirico, Mariella
Zamo, Alberto
Vitolo, Umberto
Bomben, Riccardo
Gattei, Valter
Galimberti, Sara
Di Paolo, Antonello
Rossi, Davide
Gaidano, Gianluca
Di Rocco, Alice
Cortelazzo, Sergio
Boccadoro, Mario
Balestra, Gabriella
Ladetto, Marco
BLOOD, 2017, 130
[7] A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)
Moia, R.
Ferrero, S.
Cascione, L.
Zaccaria, G. M.
Rinaldi, A.
Alessandria, B.
Grimaldi, D.
Favini, C.
Evangelista, A.
Schipani, M.
Narni, F.
Stelitano, C.
Stefani, P. M.
Benedetti, F.
Mian, M.
Casaroli, I.
Zanni, M.
Castellino, C.
Pavone, V.
Galimberti, S.
Re, F.
Rossi, D.
Cortelazzo, S.
Gaidano, G.
Ladetto, M.
Bertoni, F.
HAEMATOLOGICA, 2021, 106 (10) : 34 - 34
[8] CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI MCL0208 PHASE III TRIAL
Ferrero, S.
Rossi, D.
Bruscaggin, A.
Evangelista, A.
Di Rocco, A.
Spina, V.
Stefoni, V.
Ghione, P.
Barbero, D.
Monitillo, L.
Gomes da Silva, M.
Santoro, A.
Molinari, A.
Ferreri, A.
Piccin, A.
Cortelazzo, S.
Ladetto, M.
Gaidano, G.
HAEMATOLOGICA, 2017, 102 : 2 - 3
[9] CLINICAL IMPACT OF TP53 AND KMT2D MUTATIONS IN MCL RECEIVING HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: UPDATED RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI MCL0208 PHASE III TRIAL
Ferrero, S.
Rossi, D.
Bruscaggin, A.
Evangelista, A.
Di Rocco, A.
Spina, V.
Stefoni, V.
Ghione, P.
Barbero, D.
Monitillo, L.
da Silva, M. G.
Santoro, A.
Molinari, A.
Ferreri, A.
Piccin, A.
Cortelazzo, S.
Ladetto, M.
Gaidano, G.
HAEMATOLOGICA, 2017, 102 : 95 - 95
[10] Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial
Cordero, Francesca
Ferrero, Simone
Pernice, Simone
Genuardi, Elisa
Sirovich, Roberta
Alessandria, Beatrice
Evangelista, Andrea
Ragaini, Simone
Martelli, Maurizio
Di Rocco, Alice
Re, Alessandro
Pagani, Chiara
Stefoni, Vittorio
Cavallo, Federica
Boccomini, Carola
Balzarotti, Monica
Zilioli, Vittorio Ruggero
da Silva, Maria Gomes
Arcaini, Luca
Celli, Melania
Zaccaria, Gian Maria
Tortarolo, Dora
Cortelazzo, Sergio
Ladetto, Marco
BLOOD, 2022, 140 : 9375 - 9377

← 1 2 3 4 5 →